{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:21:02Z","timestamp":1769584862400,"version":"3.49.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Prevalence of osteoporosis in Chinese postmenopausal women has significantly increased over the past decade and oral bisphosphonates are the most potent antiresorptive drugs. The purpose of the present research was to evaluate the cost-effectiveness of oral alendronate for individuals with osteoporosis. We also assessed the impact of medication compliance and persistence on economic outcomes of alendronate and potential economic evaluations of persistence-enhancing interventions.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We constructed an individual-level state-transition model to project health outcomes and costs of oral alendronate for Chinese postmenopausal osteoporotic women. The impact of medication compliance and persistence on economic evaluation was addressed in various scenario analyses. Model inputs were derived from clinical trials and published sources, where available. Deterministic and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Compared with no treatment, alendronate treatment was associated with an additional 0.052 QALYs (quality-adjusted life-years) at an additional cost of USD 738, which yielded an incremental cost-effectiveness ratio (ICER) of USD 14,192.308\/QALY. The ICER for the different scenarios (full compliance, full persistence, and both full persistence and full compliance) was USD 4,933.333\/QALY, USD 3,006.849\/QALY, and USD 2,049.822\/QALY, respectively. One-way sensitivity analysis showed the ICER was most sensitive to variations in time horizon and residual effect. Probabilistic sensitivity analysis demonstrated that, at a willingness to pay of USD 29,340\/QALY, the probability that oral alendronate therapy will be cost-effective is approximately 80%.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The findings support the view that oral alendronate is cost-effective for the treatment of osteoporotic fractures in Chinese postmenopausal women. Medication persistence is found to have a greater impact on cost-effectiveness than compliance and interventions to improve persistence to be an efficient use of resources.<\/jats:p>","DOI":"10.3389\/fphar.2020.575893","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T09:19:51Z","timestamp":1605518391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence"],"prefix":"10.3389","volume":"11","author":[{"given":"Ruxu","family":"You","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00198-011-1627-9","article-title":"Ethnic difference of clinical vertebral fracture risk","volume":"23","author":"Bow","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B2","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays","volume":"60","author":"Brown","year":"2014","journal-title":"Can. Fam. Physician"},{"key":"B3","unstructured":"2008"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.clinthera.2013.05.019","article-title":"Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines","volume":"35","author":"Cheng","year":"2013","journal-title":"Clin. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3969\/j.issn.1006-7108","article-title":"Guidelines for the diagnosis and management of primary osteoporosis","volume":"25","year":"2019","journal-title":"Chin. J. Osteoporos."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e27049","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye","year":"2019","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e80890","DOI":"10.1371\/journal.pone.0080890","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/erp.12.8","article-title":"The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis","volume":"12","author":"Hiligsmann","year":"","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","article-title":"Utility values associated with osteoporotic fracture: a systematic review of the literature","volume":"82","author":"Hiligsmann","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jval.2012.02.001","article-title":"The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland","volume":"15","author":"Hiligsmann","year":"","journal-title":"Value Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healthpol.2010.01.014","article-title":"The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients","volume":"96","author":"Hiligsmann","year":"2010","journal-title":"Health Policy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","article-title":"Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/CIA.S242038","article-title":"Pharmacological therapy of osteoporosis: what's new?","volume":"15","author":"Iolascon","year":"2020","journal-title":"Clin. Interv. Aging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/s8756-3282(00)00381-1","article-title":"Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis","volume":"27","author":"Kanis","year":"2000","journal-title":"Bone"},{"key":"B18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","article-title":"The components of excess mortality after hip fracture","volume":"32","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","article-title":"Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA","volume":"10","author":"Kishimoto","year":"2015","journal-title":"Arch. Osteoporos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0025-6196(11)61093-8","article-title":"Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis","volume":"82","author":"Kothawala","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"B21","volume-title":"China guidelines for pharmacoeconomic evaluations","author":"Liu","year":"2011"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11657-018-0429-5","article-title":"Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China","volume":"13","author":"Liu","year":"2018","journal-title":"Arch. Osteoporos."},{"key":"B23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00198-007-0499-5","article-title":"Epidemiology of distal forearm fractures in Oslo, Norway","volume":"19","author":"Lofthus","year":"2008","journal-title":"Osteoporos. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"h3783","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s001980050113","article-title":"Fracture incidence in Olmsted county, Minnesota: comparison of urban with rural rates and changes in urban rates over time","volume":"9","author":"Melton","year":"1999","journal-title":"Osteoporos. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-017-3940-4","article-title":"Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan","volume":"28","author":"Mori","year":"","journal-title":"Osteoporos. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-016-3772-7","article-title":"Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA","volume":"28","author":"Mori","year":"","journal-title":"Osteoporos. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B30","unstructured":"2019"},{"key":"B31","volume-title":"China health statistical yearbook","year":"2018"},{"key":"B32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","article-title":"Major osteoporotic fragility fractures: risk factor updates and societal impact","volume":"7","author":"Pisani","year":"2016","journal-title":"World J. Orthop."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00198-014-2699-0","article-title":"The economic burden of fracture patients with osteoporosis in western China","volume":"25","author":"Qu","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00198-016-3502-1","article-title":"Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study","volume":"27","author":"Si","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00198-014-2636-2","article-title":"A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions","volume":"25","author":"Si","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","article-title":"Projection of osteoporosis-related fractures and costs in China: 2010-2050","volume":"26","author":"Si","year":"2015","journal-title":"Osteoporos. Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40273-014-0156-8","article-title":"Modelling the cost effectiveness of interventions for osteoporosis: issues to consider","volume":"32","author":"Stevenson","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11136-010-9762-x","article-title":"Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008","volume":"20","author":"Sun","year":"2011","journal-title":"Qual. Life Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"B40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00774-013-0484-3","article-title":"Hip fractures in Hefei, China: the Hefei osteoporosis project","volume":"32","author":"Wang","year":"2014","journal-title":"J. Bone Miner. Metabol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1089\/jwh.2017.6706","article-title":"Postmenopausal osteoporosis: a clinical review","volume":"27","author":"Watts","year":"2018","journal-title":"J. Womens Health (Larchmt)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"CD004523","DOI":"10.1002\/14651858.CD004523.pub3","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fphar.2020.00456","article-title":"Cost-effectiveness of zoledronic acid versus oral alendronate for postmenopausal osteoporotic women in China","volume":"11","author":"You","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.575893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:26:03Z","timestamp":1607369163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.575893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":43,"alternative-id":["10.3389\/fphar.2020.575893"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.575893","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"article-number":"575893"}}